Evommune (EVMN) – Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Evommune (NYSE: EVMN) recently:

• 12/6/2025 – Evommune was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/2/2025 – Evommune was upgraded by analysts at Zacks Research to a “hold” rating.
• 12/1/2025 – Evommune is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 12/1/2025 – Evommune is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $40.00 price target on the stock.
• 12/1/2025 – Evommune is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 12/1/2025 – Evommune is now covered by analysts at Morgan Stanley. They set an “overweight” rating and a $36.00 price target on the stock.
• 12/1/2025 – Evommune is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $40.00 price target on the stock.
• 12/1/2025 – Evommune was upgraded by analysts at Leerink Partnrs to a “strong-buy” rating.
• 12/1/2025 – Evommune is now covered by analysts at Leerink Partners. They set an “outperform” rating and a $42.00 price target on the stock.
• 11/20/2025 – Evommune was upgraded by analysts at Wall Street Zen to a “hold” rating.

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.